
Diabetic Retinopathy - Drug Pipeline Landscape, 2023
Description
Diabetic Retinopathy - Drug Pipeline Landscape, 2023
Diabetic retinopathy is a censorious medical disorder that affects the eyes due to inefficient insulin level in the blood of the patient. A high sugar level in the blood causes blockage of the retina's small blood capillaries, impeding blood flow resulting in cloudy or blurred vision. There are two types of diabetic retinopathy non-proliferative diabetic retinopathy and proliferative diabetic retinopathy.
A high sugar level in the blood causes blockage of the retina's small blood capillaries and impairment to blood vessels of the light-sensitive tissue of the retina is the main cause of diabetic retinopathy.
Symptoms of diabetic retinopathy are blurred vision, dark or empty spots in the vision, fluctuating vision, poor colour identification and vision loss.
Diabetic retinopathy is diagnosed by a comprehensive dilated eye exam and Fluorescein angiography.
Diabetic retinopathy is treated by diet modifications and drugs like insulin vascular endothelial growth factor inhibitors and laser treatment, eye surgery.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Diabetic Retinopathy treatment such as KSI-301, LY-09004, RTH258 and others. Key players involved in the development of therapies to treat Diabetic Retinopathy are Bayer, Boehringer Ingelheim, F. Hoffmann-La Roche AG, Hengenix Biotech Inc, OcuTerra Therapeutics Inc and others. Seven drugs are under late-stage Phase III clinical trials and sixteen drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.
In October 2022, OcuTerra published safety and biological activity data of OTT166 from phase 1b study in diabetic eye disease.
Report Highlights
Global Insight Service's, Diabetic Retinopathy - Drug Pipeline Landscape, 2023 report provides an overview of the Diabetic Retinopathy pipeline drugs. This report covers detailed insights on Diabetic Retinopathy drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Diabetic Retinopathy pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Diabetic retinopathy is a censorious medical disorder that affects the eyes due to inefficient insulin level in the blood of the patient. A high sugar level in the blood causes blockage of the retina's small blood capillaries, impeding blood flow resulting in cloudy or blurred vision. There are two types of diabetic retinopathy non-proliferative diabetic retinopathy and proliferative diabetic retinopathy.
A high sugar level in the blood causes blockage of the retina's small blood capillaries and impairment to blood vessels of the light-sensitive tissue of the retina is the main cause of diabetic retinopathy.
Symptoms of diabetic retinopathy are blurred vision, dark or empty spots in the vision, fluctuating vision, poor colour identification and vision loss.
Diabetic retinopathy is diagnosed by a comprehensive dilated eye exam and Fluorescein angiography.
Diabetic retinopathy is treated by diet modifications and drugs like insulin vascular endothelial growth factor inhibitors and laser treatment, eye surgery.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Diabetic Retinopathy treatment such as KSI-301, LY-09004, RTH258 and others. Key players involved in the development of therapies to treat Diabetic Retinopathy are Bayer, Boehringer Ingelheim, F. Hoffmann-La Roche AG, Hengenix Biotech Inc, OcuTerra Therapeutics Inc and others. Seven drugs are under late-stage Phase III clinical trials and sixteen drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.
In October 2022, OcuTerra published safety and biological activity data of OTT166 from phase 1b study in diabetic eye disease.
Report Highlights
Global Insight Service's, Diabetic Retinopathy - Drug Pipeline Landscape, 2023 report provides an overview of the Diabetic Retinopathy pipeline drugs. This report covers detailed insights on Diabetic Retinopathy drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Diabetic Retinopathy pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Table of Contents
233 Pages
- 1. Introduction
- 1.1 Diabetic Retinopathy - Pipeline Drugs, 2023 - Coverage
- 2. Disease Overview - Diabetic Retinopathy
- 2.1 Causes
- 2.2 Signs and Symptoms
- 2.3 Diagnosis
- 2.4 Disease Management
- 3. Diabetic Retinopathy - Pipeline Drugs Development - Overview
- 3.1 Comparative Analysis by Stage of Development
- 3.2 Number of Products under Development by Companies, 2023
- 3.3 Products under Development by Companies, 2023
- 4. Assessment of Therapeutics
- 4.1 Assessment by Target
- 4.2 Assessment by Mechanism of Action
- 4.3 Assessment by Molecule Type
- 4.4 Assessment by Route of Administration
- 5. Drug Profiles
- 5.1 Clinical Stage Drugs - Pre-Registration
- 5.1.1 Faricimab
- 5.1.2 HLX04
- 5.2 Clinical Stage Drugs - Phase III
- 5.2.1 Fenofibrate
- 5.2.2 KSI-301
- 5.2.3 LY09004
- 5.2.4 Ranibizumab
- 5.2.5 RTH258
- 5.2.6 Semaglutide
- 5.3 Clinical Stage Drugs - Phase II
- 5.3.1 ADVM-022
- 5.3.2 APX3330
- 5.3.3 BAY1101042
- 5.3.4 BI 764524
- 5.3.5 BI 765128
- 5.3.6 CU06-1004
- 5.3.7 Emixustat Hydrochloride
- 5.3.8 EYP-1901
- 5.3.9 GB-103
- 5.3.10 LKA651
- 5.3.11 OPL-0401
- 5.3.12 OTT16
- 5.3.13 RC28-E
- 5.3.14 RG7774
- 5.3.15 RGX-314
- 5.3.16 YD312
- 5.4 Clinical Stage Drugs - Phase I
- 5.4.1 Acuvail
- 5.4.2 APX-1004
- 5.4.3 AR-13503
- 5.4.4 AVMX-116
- 5.4.5 BSL01
- 5.4.6 FNP 120
- 5.4.7 GLY-230
- 5.4.8 MS-553
- 5.4.9 OCX-063
- 5.4.10 ST266
- 5.4.11 SYL1801
- 5.5 Clinical Stage Drugs - Preclinical
- 5.5.1 A717
- 5.5.2 AFX-5931
- 5.5.3 AMTX-100
- 5.5.4 Anti-VEGF Therapy
- 5.5.5 ARVN006
- 5.5.6 AT-003
- 5.5.7 AVD-302
- 5.5.8 BNC-1601
- 5.5.9 Drug for Diabetic Retinopathy
- 5.5.10 EB-101
- 5.5.11 EB-102
- 5.5.12 EB-105
- 5.5.13 EG-40
- 5.5.14 EGT 022
- 5.5.15 Elamipretide
- 5.5.16 FB216A1-2
- 5.5.17 HP-TAT
- 5.5.18 KNP-301
- 5.5.19 MDH-015
- 5.5.20 MDH-115
- 5.5.21 Multi Gene Eye
- 5.5.22 NN2101
- 5.5.23 NS-001
- 5.5.24 OCU200
- 5.5.25 OCX-071
- 5.5.26 PL 8177
- 5.5.27 PL-9654
- 5.5.26 PMC-40
- 5.5.27 RBM-008
- 5.5.28 Resolv ER
- 5.29 SBT-200
- 5.5.30 SER130
- 5.5.31 Sorafenib
- 5.5.32 SZN-413
- 5.5.33 TATX-21
- 5.5.34 Topical Drug for Diabetic Retinopathy
- 5.5.35 TOP-V122
- 5.5.36 UBX1325
- 5.5.37 VLTR-557
- 5.5.38 Xentry Gap -19
- 5.6 Clinical Stage Drugs - Discovery
- 5.6.1 Drug for Diabetic Retinopathy
- 5.6.2 FP-008
- 5.6.3 MCr Agonist
- 5.6.4 NG004
- 5.6.5 Norrin/Wnt7-mimetic
- 5.6.6 P-016
- 5.6.7 PTG-630
- 5.6.8 PYC-001
- 5.6.9 Renin or Prorenin Receptor Blockers
- 5.6.10 VEGFA Diabetic Retinopathy
- 5.6.11 VSCx-iPSC Vasculogenic Cell
- 6. Key Regulatory Designations
- 7. Key Deals
- 8. Key Upcoming Milestones
- 9. Key Companies Involved
- 9.1 Adverum Biotechnologies Inc
- 9.2 Aerie Pharmaceuticals
- 9.3 Afecta Pharmaceuticals Inc
- 9.4 Allergan
- 9.5 Amytrx Therapeutics Inc
- 9.6 AngiosGmbH
- 9.7 AntlerA Therapeutics Inc
- 9.8 Applied Therapeutics Inc
- 9.9 AptaBio
- 9.10 Arctic Vision Shanghai Biotechnology Co Ltd
- 9.11 Aviceda Therapeutics
- 9.12 AvirmaxInc
- 9.13 Ayuvis Research Inc
- 9.14 Bayer
- 9.15 Boehringer Ingelheim
- 9.16 BONAC Corporation
- 9.17 Caregen Co Ltd
- 9.18 CCRP Therapeutics
- 9.19 CuracleCoLtd
- 9.20 DriveTherapeuticsLLC
- 9.21 Eluminex Biosciences Ltd
- 9.22 ExcitantTherapeuticsLLC
- 9.23 Eye Gene Inc
- 9.24 EyePoint Pharmaceuticals Inc
- 9.25 F. Hoffmann-La Roche AG
- 9.26 Foresee Pharmaceuticals Co Ltd
- 9.27 Frontbio Co Ltd
- 9.28 Glycadia Inc
- 9.29 Graybug Vision Inc
- 9.30 Grupo Ferrer Internacional SA
- 9.31 Hengenix Biotech Inc
- 9.32 Iregene
- 9.33 KanaphTherapeuticsInc
- 9.34 Kato Pharmaceuticals Inc
- 9.35 Kodiak Sciences Inc
- 9.36 Kubota Vision Inc
- 9.37 Luye Pharma Group Ltd
- 9.38 MD Healthcare Inc
- 9.39 Mylan Pharmaceuticals Inc
- 9.40 Nano Pharmaceuticals LLC
- 9.41 NB Health Laboratory Co Ltd
- 9.42 NovaGo Therapeutics
- 9.43 Novartis Pharmaceuticals
- 9.44 Novelty Nobility Inc
- 9.45 Noveome Biotherapeutics Inc
- 9.46 Novo Nordisk A/S
- 9.47 OccuRx
- 9.48 Ocugen Inc
- 9.49 OcuNexus Therapeutics Inc
- 9.50 Ocuphire Pharma Inc
- 9.51 OcuTerra Therapeutics Inc
- 9.52 Oli Pass Corporation
- 9.53 OM Pharma Ltd
- 9.54 Palatin Technologies
- 9.55 PharmAbcine Inc
- 9.56 Praetego Inc
- 9.57 PYC Therapeutics
- 9.58 REGENXBIO Inc
- 9.59 RemeGen Co Ltd
- 9.60 Retinset SL
- 9.61 Ribomic Inc
- 9.62 Serodus ASA
- 9.63 Shenzhen Evergreen Therapeutics Co Ltd
- 9.64 Shenzhen MingSight Relin Pharmaceuticals Co Ltd
- 9.65 SIFI SpA
- 9.66 Singh Biotechnology LLC
- 9.67 Stealth BioTherapeutics Corp
- 9.68 Surrozen Inc
- 9.69 Sylentis SAU
- 9.70 Talem Therapeutics Inc
- 9.71 Topadur Pharma AG
- 9.72 Unity Biotechnology Inc
- 9.73 Valitor Inc
- 9.74 Valo Health, Inc
- 9.75 Vascugen Inc
- 9.76 VESSL Therapeutics Ltd
- 9.77 YD Life Science Co
- 10. Dormant Drugs
- 10.1 Inactive Drugs
- 10.2 Discontinued Drugs
- 11. Appendix
- List of Tables
- Table 1. 1 Number of Products under Development by Diabetic Retinopathy
- Table 1. 2 Number of Products under Development by Companies
- Table 1. 3 Products under Development by Companies
- Table 1. 4 Products by Targets
- Table 1. 5 Products by Mechanism of Action
- Table 1. 6 Products by Molecule Type
- Table 1. 7 Products by Route of Administration
- Table 2. 1 Clinical Trial Details - HLX04/Hengenix Biotech Inc
- Table 2. 2 Clinical Trial Details - OTT166/OcuTerra Therapeutics Inc
- Table 2. 3 Clinical Trial Details - BI 764524/Boehringer Ingelheim
- Table 2. 4 Clinical Trial Details - BAY1101042/Bayer
- Table 2. 5 Clinical Trial Details - OPL-0401/Valo Health Inc
- Table 2. 6 Clinical Trial Details - RC28-E/RemeGen Co Ltd
- Table 2. 7 Clinical Trial Details - EYP-1901/Eye Point Pharmaceuticals Inc
- Table 2. 8 Clinical Trial Details - KSI-301/Kodiak Sciences Inc
- Table 2. 9 Clinical Trial Details - RTH258/Novartis Pharmaceuticals
- Table 2. 10 Clinical Trial Details - Emixustat Hydrochloride/Kubota Vision Inc
- Table 2. 11 Clinical Trial Details - BI 765128/Boehringer Ingelheim
- Table 2. 12 Clinical Trial Details - RGX-314/REGENXBIO Inc
- Table 2. 13 Clinical Trial Details - MS-553/Shenzhen Ming Sight Relin Pharmaceuticals Co Ltd
- Table 2. 14 Clinical Trial Details - APX3330/Ocuphire Pharma Inc
- Table 2. 15 Clinical Trial Details - Ranibizumab/F. Hoffmann-La Roche AG
- Table 2. 16 Clinical Trial Details - Acuvail/Allergan
- Table 2. 17 Clinical Trial Details - ADVM-022/Adverum Biotechnologies Inc
- Table 2. 18 Clinical Trial Details - Faricimab/F. Hoffmann-La Roche AG
- Table 2. 19 Clinical Trial Details - Semaglutide/Novo Nordisk A/S
- Table 2. 20 Clinical Trial Details - Fenofibrate/Roche Pharma AG
- Table 2. 21 Clinical Trial Details - Fenofibrate/Mylan Pharmaceuticals Inc
- Table 2. 22 Clinical Trial Details - AR-13503/Aerie Pharmaceuticals
- Table 2. 23 Clinical Trial Details - LKA651/Novartis Pharmaceuticals
- Table 2. 24 Clinical Trial Details - CU06-1004/Curacle Co Ltd
- Table 2. 25 Clinical Trial Details - LY09004/Luye Pharma Group Ltd
- Table 2. 26 Clinical Trial Details - SYL1801/Sylentis SAU
- Table 2. 27 Clinical Trial Details - UBX1325/Unity Biotechnology Inc
- Table 2. 28 Clinical Trial Details - YD312/YD Life Science Co
- Table 2. 29 Clinical Trial Details - RG7774/F. Hoffmann-La Roche
- Table 3. 1 Regulatory Designations
- Table 4. 1 Inactive Drugs
- Table 4. 2 Discontinued Drugs
- List of Figures
- Figure 1.1 Number of Products under Development for Diabetic Retinopathy, 2023
- Figure 1.2 Products by Top 5 Targets and Stage of Development for Diabetic Retinopathy, 2023
- Figure 1.3 Products by Top 5 Mechanism of Action for Diabetic Retinopathy, 2023
- Figure 1.4 Products by Top 5 Molecule Type for Diabetic Retinopathy, 2023
- Figure 1.5 Products by Top 5 Route of Administration for Diabetic Retinopathy, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.